Dovetail Genomics Launches Early Access Service for FFPE Samples in Cancer Research

Transforming Cancer Research with Dovetail Genomics

Dovetail Genomics, a frontrunner in genomic innovations, has recently unveiled its early access services tailored for the analysis of FFPE (Formalin-Fixed Paraffin-Embedded) samples. This progressive step aims to significantly bolster cancer research initiatives. This service sets a new benchmark in the detection of structural variants and RNA profiling, essential elements in oncology studies.

Unveiling the Challenges of FFPE Samples

FFPE samples are a staple in clinical research, although they provide unique challenges. The fixation process typically damages nucleic acids, making them fragmented and difficult to analyze with conventional NGS (Next-Generation Sequencing) techniques. Due to these alterations, identifying large structural variants is particularly troublesome, especially in samples with low tumor fractions.

Recognizing these issues, Dovetail Genomics has harnessed the power of its proprietary linked-read chemistry, which boasts a remarkable sensitivity—achieving detection capabilities over 100 times greater than conventional short-read NGS methodologies. This leap enables researchers to perform accurate genomic analyses with FFPE samples that were previously considered too challenging for detailed study.

Enhanced Capabilities for Researchers

The Dovetail service not only increases the accessibility of genomic analyses but also improves the reliability of data extracted from these samples. Lisa Munding, the VP of Research and Development at Dovetail Genomics, emphasized that their innovative solution allows for comprehensive genome-wide structural variant detection, empowering researchers to explore cancer biology on a new level. The service is designed to analyze even samples with a tumor fraction as low as 20% at 30x coverage, ensuring high-quality outcomes that rival fresh frozen specimens.

Furthermore, Dovetail’s RNA sequencing capabilities adopt a specialized library preparation method developed by Claret Bioscience. This method is adept at processing RNA from highly fragmented samples, leading to a complete RNA profile that enhances researchers' understanding of gene expression and the complexities involved in cancer pathology.

Dr. Arul Chinnaiyan, a prominent figure at the Michigan Center for Translational Pathology, voiced his excitement about the Dovetail FFPE Assay, stating that it revolutionizes the approach towards challenging FFPE samples. His insights reveal that this tool can unveil critical genetic information by identifying clinically significant structural variants that conventional NGS approaches often overlook. This breakthrough presents highly accurate insights into structural variant-driven mechanisms in prostate cancer, enhancing the overall research capabilities in the field.

Limited Access Program

Dovetail Genomics is currently welcoming a select number of projects into their early access initiative. As part of this launch, representatives from the company are available for discussions at the 2025 Advances in Genome Biology and Technology (AGBT) conference. Researchers with pressing sample analysis needs are encouraged to connect with Matt Easterday at Dovetail for potential collaboration.

About Dovetail Genomics

Dovetail Genomics is a subsidiary of Cantata Bio and operates under Edenroc Sciences. The company focuses on linked-read technology that grants unprecedented access to genomic information. With their innovative methodologies, Dovetail Genomics tackles complex problems across various biotechnological fields, including chromatin topology analysis, genetic variation detection, and de novo chromosome assembly. By partnering with researchers, Dovetail Genomics is poised to elevate genomic research to new heights, paving the way for advancements in personal medicine and cancer treatment options.

For further details, explore Dovetail's offerings at Dovetail Genomics and follow them on social media platforms to stay updated with innovations and insights from the company.